Related Experiment Video
Updated: Aug 3, 2026
Murine Cervical Heart Transplantation Model Using a Modified Cuff Technique
Published on: October 12, 2014
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy
1University of Maryland School of Medicine, Baltimore, Maryland, USA.
Insights
Early diagnosis and prevention are crucial for cardiac allograft vasculopathy (CAV), a silent vascular disease after heart transplant. Optimizing immunosuppression and managing comorbidities can slow CAV progression, improving long-term outcomes.
Area of Science:
- Cardiology
- Transplantation Immunology
- Vascular Biology
Background:
- Cardiac allograft vasculopathy (CAV) involves intimal thickening in heart transplant recipients.
- CAV often presents asymptomatically, necessitating early detection and intervention.
- Intimal thickening predominantly occurs within the first year post-transplant.
Purpose of the Study:
- To highlight the critical need for early diagnosis and preventative strategies for CAV.
- To discuss the role of immunosuppressive therapy and comorbidity management in CAV.
- To review current and evolving treatment options for established CAV.
Main Methods:
- Literature review of CAV pathogenesis, diagnosis, and management.
- Analysis of the impact of immunosuppressive agents (e.g., calcineurin inhibitors) on CAV.
- Evaluation of pharmacologic (statins, antihypertensives, anti-CMV) and non-pharmacologic interventions.
Main Results:
- Calcineurin inhibitors are linked to renal disease, hyperlipidemia, and hypertension, exacerbating CAV.
- Statins, antihypertensive agents, and anti-CMV therapies show benefits in reducing CAV.
- Limited treatment options exist for established CAV, including retransplantation and interventional procedures.
Conclusions:
- Proactive management of immunosuppression and comorbidities is essential for preventing CAV progression.
- Emerging assessment tools are enhancing the understanding and management of CAV.
- Future strategies aim to improve both prevention and treatment of cardiac allograft vasculopathy.
Abstract:
Cardiac allograft vasculopathy (CAV), is characterized by heterogeneous proliferative thickening of the vascular intima of the cardiac allograft vasculature. Since its presentation is commonly clinically silent, early diagnosis and preventative therapy are critical. Preventative therapy including optimization of immunosuppressive therapy and treatment of comorbidities associated with CAV progression must be initiated early since most of the intimal thickening occurs during the first year posttransplant. Long-term use of calcineurin inhibitors is associated with a high incidence of chronic renal disease and also contributes to hyperlipidemia and hypertension, all of which may exacerbate CAV. In addition, statins, antihypertensive agents and anti-CMV agents all have demonstrated benefits in reducing CAV. Once established, the limited treatment options include nonpharmacologic interventions such as retransplantation, percutaneous coronary interventions, coronary artery bypass grafting, transmyocardial laser revascularization and heparin-induced/mediated extracorporeal LDL plasmapheresis (HELP). As the use of new assessment tools increases our understanding of this disease, better preventative and treatment strategies are evolving.
Related Concept Videos
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:29Cardiomyopathy V: Interprofessional Care
01:28Kidney Transplant I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management